Dendreon Corporation (NASDAQ: DNDN) is a biotechnology company whose mission is to target cancer Cancer Cancer develops when cells in the body begin to grow out of control. Normal cells grow, divide, and die. Instead of dying, cancer cells continue to grow and form new abnormal cells. Cancer cells often travel to other body parts where they grow and replace normal tissue. This spreading process is called metastasis. When cancer spreads or metastasizes, it is still named after the part of the body where it started. For example, if prostate cancer spreads to the bones, it is still prostate cancer, not bone cancer.Close and transform lives through the discovery, development, commercialization, and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering, and cell processing to produce active cellular immunotherapy (ACI) ACTIVE CELLULAR IMMUNOTHERAPY (ACI)A therapeutic platform that uses a patient’s own cells to stimulate an immune response against cancer. Close product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon’s first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010 and by the European Medicines Agency in 2013. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and has manufacturing facilities in Georgia and California.